Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia

摘要

BackgroundIn a Phase III trial, 485 patients (≥65 years) with newly diagnosed acute myeloid leukemia received decitabine 20 mg/m² intravenously for 5 days every 4 weeks or a treatment choice (supportive care or cytarabine 20 mg/m² subcutaneously for 10 days every 4 weeks).